5-Amino-1MQ

What It Is

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that sits at the intersection of SAM metabolism, NAD+ biosynthesis, and epigenetic regulation in adipose tissue. While technically not a peptide, it is widely discussed in the peptide research community due to its metabolic applications and availability through peptide-focused suppliers. NNMT methylates nicotinamide — consuming S-adenosylmethionine (SAM) in the process — and its overexpression has been associated with metabolic dysfunction, obesity, and reduced NAD+ availability. By inhibiting NNMT, 5-Amino-1MQ is proposed to increase intracellular NAD+ levels, restore SAM-dependent methylation capacity, and shift adipocyte metabolism toward energy expenditure. A landmark 2018 study demonstrated that 5-Amino-1MQ treatment increased cellular NAD+ levels by up to 40% and improved energy expenditure in adipocytes. In preclinical (mouse) models, administration reduced fat mass, improved glucose tolerance, and increased energy expenditure — even without changes in caloric intake or exercise. Notably, treated animals showed reduced adipocyte size and lower lipid accumulation without affecting lean mass. As of early 2026, no completed large-scale human clinical trials have been published, though early-phase human studies are emerging. The compound remains strictly a research tool and is not FDA-approved for any indication.

Why Researchers Study It

5-Amino-1MQ targets a fundamentally different metabolic pathway than GLP-1 agonists or other weight-management compounds — NNMT-mediated NAD+ depletion in fat tissue. Its ability to increase NAD+ by 40% and improve energy expenditure without caloric restriction positions it as a mechanistically novel approach to metabolic dysfunction. Researchers are interested in whether NNMT inhibition can complement or synergize with incretin-based therapies.

Proposed Mechanisms

• Inhibits nicotinamide N-methyltransferase (NNMT) in adipose tissue
• Increases intracellular NAD+ levels by up to 40% by preventing nicotinamide methylation
• Restores S-adenosylmethionine (SAM) availability for epigenetic methylation reactions
• Shifts adipocyte metabolism from lipid storage toward energy expenditure
• Reduces adipocyte size and lipid accumulation without affecting lean body mass

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how 5-Amino-1MQ compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] Neelakantan H. et al. — Selective and membrane-permeable small molecule inhibitors of NNMT. Biochem Pharmacol. 2018 PubMed
2. [2] 5-Amino-1MQ Research Guide: NNMT Inhibition, Fat Metabolism — SourcePeptides 2026 PubMed

Related Peptides